Loading...

Theodore Friedmann

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPediatrics
Address9500 Gilman Drive #0630
La Jolla CA 92093
Phone858-534-4268
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Lesch-Nyhan Disease: A Model for Complex Genetic, Proteomic &Metabolic Pathways
    NIH/NIDDK R24DK082840Sep 30, 2008 - Aug 31, 2014
    Role: Principal Investigator
    GENETIC ABBERATIONS IN HPRT DEFICIENCY
    NIH/NINDS R01NS044544Apr 1, 2003 - Mar 31, 2008
    Role: Principal Investigator
    ARRAY SCREENING FOR LESCH NYHAN DISEASE
    NIH/NICHD R21HD039250Jul 15, 2000 - May 31, 2003
    Role: Principal Investigator
    GENE TRANSFER TO THE VASCULAR ENDOTHELIUM
    NIH/NHLBI R01HL064730May 1, 2000 - Apr 30, 2005
    Role: Principal Investigator
    GENE THERAPY OF HYPERCHOLESTEROLEMIA
    NIH/NIDDK R01DK049023Aug 1, 1995 - Jul 31, 2000
    Role: Principal Investigator
    RETROVIRAL VECTOR BASED GENE THERAPY FOR HEMOPHILIA B
    NIH/NHLBI R01HL053680Sep 30, 1994 - Aug 31, 2000
    Role: Principal Investigator
    GENE TRANSFER FOR SUPPRESSION OF THE TUMOR PHENOTYPE
    NIH/NCI R01CA058317May 1, 1992 - Apr 30, 1995
    Role: Principal Investigator
    TRANSDUCTION OF AIRWAY EPITHELIA BY RETROVIRAL VECTORS
    NIH/NHLBI R01HL047119Apr 1, 1991 - Mar 31, 1996
    Role: Principal Investigator
    CANCER SUPPRESSION BY THE RETINOBLASTOMA GENE
    NIH/NCI P01CA051495Feb 1, 1990 - Jan 31, 1995
    Role: Principal Investigator
    PHYSICAL MAP OF THE HUMAN X CHROMOSOME
    NIH/NHGRI R01HG000309Jul 1, 1989 - Jun 30, 1995
    Role: Principal Investigator
    PHYSICAL MAP OF THE HUMAN X CHROMOSOME
    NIH/NIGMS R01GM040790Jul 1, 1989 - Jun 30, 1994
    Role: Principal Investigator
    MODELS FOR CNS GENE THERAPY
    NIH/NICHD R01HD020034Apr 1, 1985 - Mar 31, 1996
    Role: Principal Investigator
    THE HUMAN HPRT GENE AND X CHROMOSOME ORGANIZATION
    NIH/NIGMS R01GM028223Aug 1, 1980 - Jul 31, 1987
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang G, Karanikolou A, Verdouka I, Friedmann T, Pitsiladis Y. Next Generation "Omics" Approaches in the "Fight" against Blood Doping. Med Sport Sci. 2017; 62:119-128. PMID: 28571016.
      View in: PubMed
    2. Friedmann T. Happy Anniversary. Mol Ther. 2007 Jun; 15(6):1035-1036. PMID: 28182920.
      View in: PubMed
    3. Friedmann T. An ASGCT Perspective on the National Academies Genome Editing Summit. Mol Ther. 2016 Feb; 24(1):1-2. PMID: 26854182; PMCID: PMC4754555 [Available on 02/01/17].
    4. Friedmann T, Jonlin EC, King NMP, Torbett BE, Wivel NA, Kaneda Y, Sadelain M. ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Mol Ther. 2015 Aug; 23(8):1282. PMID: 26227250; PMCID: PMC4817859.
    5. Kang TH, Friedmann T. Alzheimer's disease shares gene expression aberrations with purinergic dysregulation of HPRT deficiency (Lesch-Nyhan disease). Neurosci Lett. 2015 Mar 17; 590:35-9. PMID: 25636690.
      View in: PubMed
    6. Kang TH, Park Y, Bader JS, Friedmann T. The housekeeping gene hypoxanthine guanine phosphoribosyltransferase (HPRT) regulates multiple developmental and metabolic pathways of murine embryonic stem cell neuronal differentiation. PLoS One. 2013; 8(10):e74967. PMID: 24130677; PMCID: PMC3794013.
    7. Friedmann T, Flenker U, Georgakopoulos C, Alsayrafi M, Sottas PE, Williams SA, Gill RD. Evolving concepts and techniques for anti-doping. Bioanalysis. 2012 Jul; 4(13):1667-80. PMID: 22831482.
      View in: PubMed
    8. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, Aiuti A, Naldini L, Baum C, von Kalle C, Kiem HP, Montini E, Bushman F, Sorrentino BP, Carrondo M, Malech H, Gahrton G, Shapiro R, Wolff L, Rosenthal E, Jambou R, Zaia J, Kohn DB. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther. 2012 Jun; 20(6):1084-94. PMID: 22652996; PMCID: PMC3369284.
    9. Mastrangelo L, Kim JE, Miyanohara A, Kang TH, Friedmann T. Purinergic signaling in human pluripotent stem cells is regulated by the housekeeping gene encoding hypoxanthine guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A. 2012 Feb 28; 109(9):3377-82. PMID: 22331909; PMCID: PMC3295269.
    10. Friedmann T. The successful clinical use of viral vectors for human gene therapy. Preface. Methods Enzymol. 2012; 507:xvii-xx. PMID: 22365783.
      View in: PubMed
    11. Guibinga GH, Hrustanovic G, Bouic K, Jinnah HA, Friedmann T. MicroRNA-mediated dysregulation of neural developmental genes in HPRT deficiency: clues for Lesch-Nyhan disease? Hum Mol Genet. 2012 Feb 01; 21(3):609-22. PMID: 22042773; PMCID: PMC3259014.
    12. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou MY, Pattison J, Torzewski M, Sollors J, Friedmann T, Lai NC, Hammond HK, Getz GS, Reardon CA, Li AC, Banka CL, Witztum JL. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011 Oct 11; 58(16):1715-27. PMID: 21982317; PMCID: PMC3230644.
    13. Kang TH, Guibinga GH, Jinnah HA, Friedmann T. HPRT deficiency coordinately dysregulates canonical Wnt and presenilin-1 signaling: a neuro-developmental regulatory role for a housekeeping gene? PLoS One. 2011 Jan 28; 6(1):e16572. PMID: 21305049.
      View in: PubMed
    14. Guibinga GH, Friedmann T. Preparation of pseudotyped lentiviral vectors resistant to inactivation by serum complement. Cold Spring Harb Protoc. 2010 Jul 01; 2010(7):pdb.prot5420. PMID: 20647353.
      View in: PubMed
    15. Friedmann T. How close are we to gene doping? Hastings Cent Rep. 2010 Mar-Apr; 40(2):20-2. PMID: 20391845.
      View in: PubMed
    16. Friedmann T, Rabin O, Frankel MS. Ethics. Gene doping and sport. Science. 2010 Feb 05; 327(5966):647-8. PMID: 20133558.
      View in: PubMed
    17. King CC, Bouic K, Friedmann T. A fractionation method to identify qauntitative changes in protein expression mediated by IGF-1 on the proteome of murine C2C12 myoblasts. Proteome Sci. 2009 Aug 11; 7:28. PMID: 19664293; PMCID: PMC2732595.
    18. Guibinga GH, Hsu S, Friedmann T. Deficiency of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis. Mol Ther. 2010 Jan; 18(1):54-62. PMID: 19672249; PMCID: PMC2839227.
    19. Nienhuis A, Friedmann T. An integrated funding mechanism for clinical trials in human gene therapy. Mol Ther. 2009 Jul; 17(7):1117-8. PMID: 19564863; PMCID: PMC2835213.
    20. Bhasker CR, Friedmann T. Insulin-like growth factor-1 coordinately induces the expression of fatty acid and cholesterol biosynthetic genes in murine C2C12 myoblasts. BMC Genomics. 2008 Nov 11; 9:535. PMID: 19014463; PMCID: PMC2628395.
    21. Friedmann T. The ASGT and ethical codes for clinical research. Mol Ther. 2008 Oct; 16(10):1643-4. PMID: 18813316.
      View in: PubMed
    22. Guibinga GH, Song S, Loring J, Friedmann T. Characterization of the gene delivery properties of baculoviral-based virosomal vectors. J Virol Methods. 2008 Mar; 148(1-2):277-82. PMID: 18207578.
      View in: PubMed
    23. Friedmann T. A new serious adverse event in a gene therapy study. Mol Ther. 2007 Nov; 15(11):1899-900. PMID: 17948042.
      View in: PubMed
    24. Guo LT, Friedmann T, King CC. Partial characterization of the proteome of the mouse striatum. Proteomics. 2007 Nov; 7(21):3867-9. PMID: 17922512.
      View in: PubMed
    25. Friedmann T. A decade of accomplishments: gene therapy and the ASGT. Mol Ther. 2007 Sep; 15(9):1576-8. PMID: 17710079.
      View in: PubMed
    26. Song S, Friedmann T. Tissue-specific aberrations of gene expression in HPRT-deficient mice: functional complexity in a monogenic disease? Mol Ther. 2007 Aug; 15(8):1432-43. PMID: 17505472.
      View in: PubMed
    27. Schneider AJ, Friedmann T. Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet. 2006; 51:1-110. PMID: 16504745.
      View in: PubMed
    28. Guibinga GH, Friedmann T. Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein. Mol Ther. 2005 Apr; 11(4):645-51. PMID: 15771967.
      View in: PubMed
    29. Friedmann T. Lessons for the stem cell discourse from the gene therapy experience. Perspect Biol Med. 2005; 48(4):585-91. PMID: 16227669.
      View in: PubMed
    30. Friedmann T. Clinical gene therapy: lessons from the ether dome. Mol Ther. 2004 Aug; 10(2):205-6. PMID: 15294165.
      View in: PubMed
    31. Smith DW, Friedmann T. Discrepant effects of culture conditions on survival and function of dopaminergic neurons. Neuroreport. 2004 Apr 29; 15(6):1025-8. PMID: 15076727.
      View in: PubMed
    32. Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther. 2004 Jan; 9(1):76-84. PMID: 14741780.
      View in: PubMed
    33. Friedmann T. Plus ├ža change... Mol Ther. 2003 Nov; 8(5):701. PMID: 14632022.
      View in: PubMed
    34. Friedmann T. Gene therapy's new era: a balance of unequivocal benefit and unequivocal harm. Mol Ther. 2003 Jul; 8(1):5-7. PMID: 12872762.
      View in: PubMed
    35. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther. 2002 May; 5(5 Pt 1):538-46. PMID: 11991744.
      View in: PubMed
    36. Visser JE, Smith DW, Moy SS, Breese GR, Friedmann T, Rothstein JD, Jinnah HA. Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. Brain Res Dev Brain Res. 2002 Feb 28; 133(2):127-39. PMID: 11882343.
      View in: PubMed
    37. Friedmann T. Stanfield Rogers: insights into virus vectors and failure of an early gene therapy model. Mol Ther. 2001 Oct; 4(4):285-8. PMID: 11592829.
      View in: PubMed
    38. Friedmann T, Noguchi P, Mickelson C. The evolution of public review and oversight mechanisms in human gene transfer research: joint roles of the FDA and NIH. Curr Opin Biotechnol. 2001 Jun; 12(3):304-7. PMID: 11404110.
      View in: PubMed
    39. Friedmann T, Koss JO. Gene transfer and athletics- an impending problem. Mol Ther. 2001 Jun; 3(6):819-20. PMID: 11407894.
      View in: PubMed
    40. Friedmann T. Medical ethics. Principles for human gene therapy studies. Science. 2000 Mar 24; 287(5461):2163-5. PMID: 10744537.
      View in: PubMed
    41. Friedmann T. Changing roles for academia and industry in genetics and gene therapy. Mol Ther. 2000 Jan; 1(1):9-11. PMID: 10933906.
      View in: PubMed
    42. Friedmann T. The road toward human gene therapy--a 25-year perspective. Ann Med. 1997 Dec; 29(6):575-7. PMID: 9562527.
      View in: PubMed